Medtronic Return on Equity (ROE) Growth & History (MDT)
Medtronic's return on equity was 9.85% for fiscal 2026.
View full Medtronic company overviewMedtronic annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2026 | 2026-04-24 | 9.85% | +0.36 pp |
| 2025 | 2025-04-25 | 9.49% | +2.26 pp |
| 2024 | 2024-04-26 | 7.23% | +0.00 pp |
| 2023 | 2023-04-28 | 7.22% | −2.47 pp |
| 2022 | 2022-04-29 | 9.69% | +2.63 pp |
| 2021 | 2021-04-30 | 7.06% | −2.44 pp |
| 2020 | 2020-04-24 | 9.50% | +0.31 pp |
| 2019 | 2019-04-26 | 9.19% | +3.04 pp |
| 2018 | 2018-04-27 | 6.15% | −1.73 pp |
| 2017 | 2017-04-28 | 7.88% | +1.16 pp |
| 2016 | 2016-04-29 | 6.72% | −0.64 pp |
| 2015 | 2015-04-24 | 7.36% | −8.72 pp |
| 2014 | 2014-04-25 | 16.08% | — |
Medtronic quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q1 2027 | 2026-07-31 | 2.95% | +0.78 pp |
| Q4 2026 | 2026-04-24 | 2.53% | +0.36 pp |
| Q3 2026 | 2026-01-31 | 2.33% | −0.31 pp |
| Q3 2026 | 2026-01-23 | 2.34% | −0.30 pp |
| Q2 2026 | 2025-10-24 | 2.85% | +0.21 pp |
| Q1 2026 | 2025-07-25 | 2.17% | +0.05 pp |
| Q4 2025 | 2025-04-25 | 2.17% | +0.89 pp |
| Q3 2025 | 2025-01-24 | 2.64% | +0.08 pp |
| Q2 2025 | 2024-10-25 | 2.63% | +0.86 pp |
| Q1 2025 | 2024-07-26 | 2.12% | +0.58 pp |
| Q4 2024 | 2024-04-26 | 1.28% | −1.01 pp |
| Q3 2024 | 2024-01-26 | 2.56% | +0.20 pp |
| Q2 2024 | 2023-10-27 | 1.77% | +0.95 pp |
| Q1 2024 | 2023-07-28 | 1.54% | −0.22 pp |
| Q4 2023 | 2023-04-28 | 2.29% | −0.53 pp |
| Q3 2023 | 2023-01-27 | 2.37% | −0.47 pp |
| Q2 2023 | 2022-10-28 | 0.82% | −1.72 pp |
| Q1 2023 | 2022-07-29 | 1.77% | +0.28 pp |
| Q4 2022 | 2022-04-29 | 2.83% | +0.16 pp |
| Q3 2022 | 2022-01-28 | 2.83% | +0.31 pp |
| Q2 2022 | 2021-10-29 | 2.53% | +1.56 pp |
| Q1 2022 | 2021-07-30 | 1.48% | +0.52 pp |
| Q4 2021 | 2021-04-30 | 2.66% | +1.40 pp |
| Q3 2021 | 2021-01-29 | 2.52% | −1.22 pp |
| Q2 2021 | 2020-10-30 | 0.97% | −1.73 pp |
| Q1 2021 | 2020-07-31 | 0.96% | −0.76 pp |
| Q4 2020 | 2020-04-24 | 1.26% | −1.09 pp |
| Q3 2020 | 2020-01-24 | 3.74% | +1.19 pp |
| Q2 2020 | 2019-10-25 | 2.70% | +0.47 pp |
| Q1 2020 | 2019-07-26 | 1.72% | −0.41 pp |
| Q4 2019 | 2019-04-26 | 2.35% | −0.55 pp |
| Q3 2019 | 2019-01-25 | 2.55% | +5.28 pp |
| Q2 2019 | 2018-10-26 | 2.23% | −1.72 pp |
| Q1 2019 | 2018-07-27 | 2.13% | +0.12 pp |
| Q4 2018 | 2018-04-27 | 2.89% | +0.56 pp |
| Q3 2018 | 2018-01-26 | −2.73% | −4.38 pp |
| Q2 2018 | 2017-10-27 | 3.95% | +1.74 pp |
| Q1 2018 | 2017-07-28 | 2.01% | +0.21 pp |
| Q4 2017 | 2017-04-28 | 2.34% | +0.19 pp |
| Q3 2017 | 2017-01-27 | 1.65% | −0.48 pp |
| Q2 2017 | 2016-10-28 | 2.21% | +1.22 pp |
| Q1 2017 | 2016-07-29 | 1.81% | +0.26 pp |
| Q4 2016 | 2016-04-29 | 2.15% | +2.15 pp |
| Q3 2016 | 2016-01-29 | 2.12% | — |
| Q2 2016 | 2015-10-30 | 0.99% | — |
| Q1 2016 | 2015-07-31 | 1.55% | — |
| Q4 2015 | 2015-04-24 | −0.00% | — |
Medtronic return on equity trends
Over the last five fiscal years, Medtronic's return on equity increased from 7.06% to 9.85%, a change of +2.79 percentage points. The latest reported quarter, Q1 2027, shows 2.95%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Medtronic source filings ↗Community posts
Medtronic begins European clinical use of its Stealth AXiS surgical system
Medtronic ($MDT) announced the first European procedures using its Stealth AXiS surgical system, with more than 23 procedures performed across seven sites in Germany, the UK, Italy and Spain. The initial experience includes spinal surgery. ...